T-Mobile Unit Sprint to Redeem $1.5 Billion of Notes-February 2024-www.financetom.com

T-Mobile Unit Sprint to Redeem $1.5 Billion of Notes

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

T-Mobile Unit Sprint to Redeem $1.5 Billion of Notes

Oct 17, 2024 2:00 PM

05:03 PM EDT, 10/16/2024 (MT Newswires) -- T-Mobile US ( TMUS ) said Wednesday that its unit Sprint will redeem $1.5 billion 7.625% notes due Feb. 15, 2025, on Nov. 15.

The redemption price will be 100% of the principal amount, plus accrued and unpaid interest, T-Mobile said.

Price: 221.00, Change: +1.24, Percent Change: +0.56

Previous page： Next page： Nestle lowers full-year guidance on quicker-than-expected price fall

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Jul 24, 2024

...

Nestle lowers full-year guidance on quicker-than-expected price fall

Jul 24, 2024

(Reuters) -Nestle reported half-year sales growth below analysts' forecasts on Thursday and lowered its full-year organic sales growth guidance to at least 3% from about 4% previously. The world's biggest packaged food company managed to increase its volumes amid worries that price hikes would alienate shoppers. The Swiss company expects pricing to come down faster than expected, prompting it to...

STMicroelectronics cuts full-year outlook for second time

Jul 24, 2024

July 25 (Reuters) - Franco-Italian chipmaker STMicroelectronics (STM) on Thursday cut its full-year revenues guidance for the second time this year as industrial customer orders did not improve and automotive demand declined. The company, whose clients include Tesla and Apple ( AAPL ) , said it expects revenue in the range of $13.2 billion to $13.7 billion for 2024, against...

Roche lifts 2024 profit guidance on drug sales

Jul 24, 2024

July 25 (Reuters) - Roche on Thursday raised its full-year earnings guidance, driven by high demand for newer drugs such as eye medicine Vabysmo. Core earnings per share are targeted to grow in the high single digit range, excluding the effect of currency swings and the resolution of tax disputes in 2023, it said in a statement. It had previously...